Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. (Q34612068)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. |
scientific article |
Statements
1 reference
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. (English)
1 reference
Ursula Vehling-Kaiser
1 reference
Ludwig Fischer von Weikersthal
1 reference
Stefan Boeck
1 reference
Dirk Waldschmidt
1 reference
Erika Kettner
1 reference
Angela Märten
1 reference
Cornelia Winkelmann
1 reference
Stefan Klein
1 reference
Georgi Kojouharoff
1 reference
Thomas Gauler
1 reference
Michael R Clemens
1 reference
Michael Geissler
1 reference
Tim F Greten
1 reference
Susanna Hegewisch-Becker
1 reference
Sascha Neugebauer
1 reference
Volker Heinemann
1 reference
1 January 2010
1 reference
1 reference
21
1 reference
1
1 reference
94-100
1 reference
Identifiers
1 reference
1 reference